Diabetes epidemic triggers soaring drug market

The New York Times looks at a group of new and upcoming diabetes drugs that are expected to play a big role in treating an epidemic of diabetes in the U.S. More than 20 million Americans have diabetes and with a rising tide of obesity, that number is expected to trend steadily northward. The market for diabetes drugs, meanwhile, is expected to shoot up from $15 billion to $25 billion in just five years, with much of that going to Byetta and Exubera. Two experimental drugs--Galvus and Januvia--and expected to gain FDA approval in the near future, and both figure to be blockbusters.

- read this New York Times article